41389-17-7

Upstream product

• 585-49-9 1-(prop-2-en-1-yloxy)-3-(trifluoromethyl)benzene 
• 98-17-9 3-Trifluoromethylphenol 

Downstream Products

• 61761-32-8 5-fluoronaphthalen-1-ol 
• 1202643-65-9 2-propyl-3-trifluoromethyl-phenol 

Relevant academic research and scientific papers

NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS

The present invention is concerned with novel substituted pyrido-piperazinone derivatives of Formula (I) wherein R1, R2, R3, R4, R5, L, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

A transition-metal-free synthesis of fluorinated naphthols

Herein, we describe a transition-metal-free protocol for the conversion of simple 2-allyl-3-(trifluoromethyl)phenols into substituted 5-fluoronaphthalen-1- ols. The key events of this reaction include the selective activation of two C-F bonds and formatio

NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS

The present invention is concerned with novel substituted pyrido-piperazinone derivatives of Formula (I) wherein R1, R2, R3, R4, R5, L, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

Using geminal dicationic ionic liquids as solvents for high-temperature organic reactions

(Chemical Equation Presented) Several organic reactions conducted at high temperatures, including the isomerization reaction, the Claisen rearrangement, and the Diels-Alder reaction, were investigated in three geminal dicationic ionic liquids with high thermal stability. High to moderate yields of the products for most entries were obtained. Advantages of these approaches are discussed. These ionic liquids were shown to be recyclable. The utility of these ionic liquid solvents for high-temperature organic reactions was demonstrated.

Substituent effects on the rate constants for the photo-claisen rearrangement of allyl aryl ethers

The photochemistry of 11 substituted allyl 4-X- and 3-X-aryl ethers 3 (ArOCH2-CH=CH2) has been examined in both methanol and cyclohexane as solvents. The ethers react by the photo-Claisen rearrangement to give allyl substituted phenols as the major primary photoproducts, as expected from the well-established radical pair mechanism. The excited singlet state properties (absorption spectra, fluorescence spectra, fluorescence quantum yields, and singlet lifetimes) were compared with a parallel set of unreactive 4-X- and 3-X-anisoles 4. The excited-state properties of three substituted 4-X-aryl 4-(1-butenyl) ethers 14 (ArOCH2CH2-CH=CH2) were also examined. The model compounds 4 and the reactive allyl ethers 3 have essentially identical rate constants for the excited-state processes with the exception of khoms, the rate constant for homolytic cleavage from S1 of the allyl ethers to give the radical pair. The difference between the fluorescence quantum yields and/or singlet lifetimes for 3 and 4 were used to obtain values of khoms for all of the allyl ethers. These values exhibit a large substituent effect, spanning almost 2 orders of magnitude with electron-donating groups (CH3O, CH3) accelerating the reaction and electron-withdrawing ones (CN, CF3) slowing it down. The parallel range of rate constants observed in both methanol and cyclohexane indicates that ion pairs are not important intermediates in these rearrangements. Quantum yields of reaction (Φr) for several of the more reactive ethers demonstrate that neither these values nor rate constants of reaction (khomr) derived from them are reliable measures of the actual excited-state process. In fact, the khomr values are significantly lower than the khoms ones, indicating that the radical pairs undergo recombination to generate starting material. Finally, the khoms rate constants were found to parallel a trend for the change in bond dissociation energy (ΔBDE) for the O-C (allyl) bond of the allyl ethers, indicating that other possible substituent effects are of minor importance.

Claisen Rearrangement of meta-Substituted Allyl Phenyl Ethers

Electron-releasing substituents at the 3-position of allyl phenyl ethers favour Claisen rearangement of the allyl group to the 6-position, whereas electron-acceptors favour migration to the 2-position. 2-Acylhydroquinone 4-allyl ethers yield, predominantly, the 3-allyl isomers, probably because internal hydrogen bonding confers naphthalenoid character on the aryl residue.